Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, agrigenomics, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. The company has a strategic partnership with Loxo Oncology, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and strategic collaboration with Bristol-Myers Squibb Company. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:ILMN
CUSIP45232710
Phone858-202-4500
Debt
Debt-to-Equity Ratio0.23
Current Ratio2.71
Quick Ratio2.41
Price-To-Earnings
Trailing P/E Ratio77.31
Forward P/E Ratio63.47
P/E Growth3.26
Sales & Book Value
Annual Sales$2.75 billion
Price / Sales16.51
Cash Flow$5.3850 per share
Price / Cash57.40
Book Value$18.83 per share
Price / Book16.42
Profitability
EPS (Most Recent Fiscal Year)$4.00
Net Income$726 million
Net Margins19.31%
Return on Equity24.93%
Return on Assets13.72%
Miscellaneous
Employees6,200
Outstanding Shares147,000,000
Market Cap$44,907.03
Illumina (NASDAQ:ILMN) Frequently Asked Questions
What is Illumina's stock symbol?
Illumina trades on the NASDAQ under the ticker symbol "ILMN."
How were Illumina's earnings last quarter?
Illumina, Inc. (NASDAQ:ILMN) announced its earnings results on Tuesday, April, 24th. The life sciences company reported $1.45 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.02 by $0.43. The life sciences company earned $782 million during the quarter, compared to the consensus estimate of $744.30 million. Illumina had a net margin of 19.31% and a return on equity of 24.93%. The firm's revenue for the quarter was up 30.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.64 earnings per share. View Illumina's Earnings History.
When is Illumina's next earnings date?
What guidance has Illumina issued on next quarter's earnings?
Illumina updated its FY18 earnings guidance on Tuesday, April, 24th. The company provided earnings per share guidance of $4.75-4.85 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.59. The company issued revenue guidance of +15-16% to ~$3.16-3.19 billion, compared to the consensus revenue estimate of $3.14 billion.
What price target have analysts set for ILMN?
19 brokerages have issued 1 year target prices for Illumina's shares. Their predictions range from $200.00 to $330.00. On average, they anticipate Illumina's share price to reach $265.1875 in the next year. This suggests that the stock has a possible downside of 14.2%. View Analyst Ratings for Illumina.
What is the consensus analysts' recommendation for Illumina?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 1 sell rating, 4 hold ratings, 13 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Illumina stock?
Here are some recent quotes from research analysts about Illumina stock:
- 1. According to Zacks Investment Research, "In the last three months, Illumina outperformed its industry. The company’s recent strategic collaborations are expected to expand its product portfolio. This apart an improving margin scenario should also instill confidence on the stock. Currently, Illumina is focusing on product innovation through research and development as well, which is evident from the launch of iSeq 100 Sequencing System recently. Post a promising fourth-quarter show, we expect Illumina to maintain its growth momentum on continued uptake of sequencing consumables, instruments and microarray portfolios. On the flip side, the company is operating in a tough competitive landscape which is a concern. Further, the stock looks a bit overvalued at the moment." (4/16/2018)
- 2. Canaccord Genuity analysts commented, "Shipments to China grew +16% and we believe China is likely to be a double-digit grower for ILMN over the next several years, driven by the Chinese Precision Medicine Initiative," (8/7/2017)
Who are some of Illumina's key competitors?
Some companies that are related to Illumina include Agilent Technologies (A), Waters (WAT), Mettler-Toledo International (MTD), Bio-Rad Laboratories, Inc. Class A Common Stock (BIO), Bio-Rad Laboratories, Inc. Class B (BIO.B), PerkinElmer (PKI), Integra Lifesciences (IART), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM) and Harvard Bioscience (HBIO).
Who are Illumina's key executives?
Illumina's management team includes the folowing people:
- Mr. Jay T. Flatley, Exec. Chairman (Age 65)
- Mr. Francis A. deSouza, CEO, Pres & Director (Age 47)
- Mr. Sam A. Samad, CFO & Sr. VP (Age 48)
- Mr. Omead Ostadan, Exec. VP of Operations and Products (Age 46)
- Mr. Marc A. Stapley, Exec. VP of Strategy & Corp. Devel. (Age 48)
Has Illumina been receiving favorable news coverage?
Headlines about ILMN stock have been trending positive recently, according to Accern Sentiment. The research group rates the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Illumina earned a coverage optimism score of 0.26 on Accern's scale. They also gave media headlines about the life sciences company an impact score of 48.56 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are Illumina's major shareholders?
Illumina's stock is owned by many different of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (11.25%), Fred Alger Management Inc. (0.53%), Assenagon Asset Management S.A. (0.18%), American Capital Management Inc. (0.17%), Bank of Montreal Can (0.10%) and Scout Investments Inc. (0.06%). Company insiders that own Illumina stock include A Blaine Bowman, Charles Dadswell, Daniel Bradbury, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Michel Bouchard, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Robert S Epstein and Roy A Whitfield. View Institutional Ownership Trends for Illumina.
Which major investors are selling Illumina stock?
ILMN stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Scout Investments Inc., Hartford Investment Management Co., Boston Advisors LLC, American Capital Management Inc., Retirement Systems of Alabama, Mitsubishi UFJ Asset Management UK Ltd. and Gateway Investment Advisers LLC. Company insiders that have sold Illumina company stock in the last year include A Blaine Bowman, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Michel Bouchard, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan and Robert S Epstein. View Insider Buying and Selling for Illumina.
Which major investors are buying Illumina stock?
ILMN stock was bought by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Assenagon Asset Management S.A., Bank of Montreal Can, Peregrine Capital Management LLC, Nisa Investment Advisors LLC, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Verde Servicos Internacionais S.A. and State of Alaska Department of Revenue. View Insider Buying and Selling for Illumina.
How do I buy shares of Illumina?
Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Illumina's stock price today?
One share of ILMN stock can currently be purchased for approximately $309.10.
How big of a company is Illumina?
Illumina has a market capitalization of $44.91 billion and generates $2.75 billion in revenue each year. The life sciences company earns $726 million in net income (profit) each year or $4.00 on an earnings per share basis. Illumina employs 6,200 workers across the globe.
How can I contact Illumina?
Illumina's mailing address is 5200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]
MarketBeat Community Rating for Illumina (NASDAQ ILMN)
MarketBeat's community ratings are surveys of what our community members think about Illumina and other stocks. Vote "Outperform" if you believe ILMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ILMN will underperform the S&P 500 over the long term. You may vote once every thirty days.
